Selected research
Market Outlook & Growth Opportunities
Global Medical Device Viral Inactivation Testing Market Outlook and Growth Opportunities 2026
Market perspective
The global Medical Device Viral Inactivation Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Medical Device Viral Inactivation Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Medical Device Viral Inactivation Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Medical Device Viral Inactivation Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Medical Device Viral Inactivation Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Medical Device Viral Inactivation Testing market include Charles River, Perfectus Biomed (NAMSA), Eurofins Scientific, Nelson Labs, Texcell, Intertek Group, LabCorp, Syensqo and SGS, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Medical Device Viral Inactivation Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Medical Device Viral Inactivation Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Medical Device Viral Inactivation Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Medical Device Viral Inactivation Testing market.
Medical Device Viral Inactivation Testing Segment by Company
Charles River
Perfectus Biomed (NAMSA)
Eurofins Scientific
Nelson Labs
Texcell
Intertek Group
LabCorp
Syensqo
SGS
Pacific BioLabs
Creative Biogene
ProPharma Group
Cormica Lab (Wickham Micro)
CTI
WuXi AppTec
Medical Device Viral Inactivation Testing Segment by Type
DNA-based
RNA-based
Medical Device Viral Inactivation Testing Segment by Application
Active Implant Medical Devices
Active Medical Equipment
In Vitro Diagnostic Equipment
Ophthalmic Medical Equipment
Vascular Medical Equipment
Other
Medical Device Viral Inactivation Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Medical Device Viral Inactivation Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Medical Device Viral Inactivation Testing key companies, revenue, market share, and recent developments.
3. To split the Medical Device Viral Inactivation Testing breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Medical Device Viral Inactivation Testing market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Medical Device Viral Inactivation Testing significant trends, drivers, influence factors in global and regions.
6. To analyze Medical Device Viral Inactivation Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medical Device Viral Inactivation Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medical Device Viral Inactivation Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medical Device Viral Inactivation Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Medical Device Viral Inactivation Testing industry.
Chapter 3: Detailed analysis of Medical Device Viral Inactivation Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Medical Device Viral Inactivation Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Medical Device Viral Inactivation Testing in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Medical Device Viral Inactivation Testing Industry Trends
Table 2. Medical Device Viral Inactivation Testing Industry Drivers
Table 3. Medical Device Viral Inactivation Testing Industry Opportunities and Challenges
Table 4. Medical Device Viral Inactivation Testing Industry Restraints
Table 5. Global Medical Device Viral Inactivation Testing Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Medical Device Viral Inactivation Testing Revenue Share by Company (2021-2026)
Table 7. Global Medical Device Viral Inactivation Testing Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Medical Device Viral Inactivation Testing Key Company Manufacturing Base & Headquarters
Table 9. Global Medical Device Viral Inactivation Testing Company, Product Type & Application
Table 10. Global Medical Device Viral Inactivation Testing Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Medical Device Viral Inactivation Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of DNA-based
Table 15. Significant Companies of RNA-based
Table 16. Global Medical Device Viral Inactivation Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 17. Global Medical Device Viral Inactivation Testing Sales Value by Type (2021-2026) & (US$ Million)
Table 18. Global Medical Device Viral Inactivation Testing Sales Value by Type (2027-2032) & (US$ Million)
Table 19. Global Medical Device Viral Inactivation Testing Sales Value Share by Type (2021-2026)
Table 20. Global Medical Device Viral Inactivation Testing Sales Value Share by Type (2027-2032)
Table 21. Significant Companies of Active Implant Medical Devices
Table 22. Significant Companies of Active Medical Equipment
Table 23. Significant Companies of In Vitro Diagnostic Equipment
Table 24. Significant Companies of Ophthalmic Medical Equipment
Table 25. Significant Companies of Vascular Medical Equipment
Table 26. Significant Companies of Other
Table 27. Global Medical Device Viral Inactivation Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 28. Global Medical Device Viral Inactivation Testing Sales Value by Application (2021-2026) & (US$ Million)
Table 29. Global Medical Device Viral Inactivation Testing Sales Value by Application (2027-2032) & (US$ Million)
Table 30. Global Medical Device Viral Inactivation Testing Sales Value Share by Application (2021-2026)
Table 31. Global Medical Device Viral Inactivation Testing Sales Value Share by Application (2027-2032)
Table 32. Global Medical Device Viral Inactivation Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 33. Global Medical Device Viral Inactivation Testing Sales Value by Region (2021-2026) & (US$ Million)
Table 34. Global Medical Device Viral Inactivation Testing Sales Value Share by Region (2021-2026)
Table 35. Global Medical Device Viral Inactivation Testing Sales Value by Region (2027-2032) & (US$ Million)
Table 36. Global Medical Device Viral Inactivation Testing Sales Value Share by Region (2027-2032)
Table 37. Global Medical Device Viral Inactivation Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 38. Global Medical Device Viral Inactivation Testing Sales Value by Country (2021-2026) & (US$ Million)
Table 39. Global Medical Device Viral Inactivation Testing Sales Value Market Share by Country (2021-2026)
Table 40. Global Medical Device Viral Inactivation Testing Sales Value by Country (2027-2032) & (US$ Million)
Table 41. Global Medical Device Viral Inactivation Testing Sales Value Market Share by Country (2027-2032)
Table 42. Charles River Company Information
Table 43. Charles River Business Overview
Table 44. Charles River Medical Device Viral Inactivation Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 45. Charles River Medical Device Viral Inactivation Testing Product Portfolio
Table 46. Charles River Recent Development
Table 47. Perfectus Biomed (NAMSA) Company Information
Table 48. Perfectus Biomed (NAMSA) Business Overview
Table 49. Perfectus Biomed (NAMSA) Medical Device Viral Inactivation Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 50. Perfectus Biomed (NAMSA) Medical Device Viral Inactivation Testing Product Portfolio
Table 51. Perfectus Biomed (NAMSA) Recent Development
Table 52. Eurofins Scientific Company Information
Table 53. Eurofins Scientific Business Overview
Table 54. Eurofins Scientific Medical Device Viral Inactivation Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 55. Eurofins Scientific Medical Device Viral Inactivation Testing Product Portfolio
Table 56. Eurofins Scientific Recent Development
Table 57. Nelson Labs Company Information
Table 58. Nelson Labs Business Overview
Table 59. Nelson Labs Medical Device Viral Inactivation Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 60. Nelson Labs Medical Device Viral Inactivation Testing Product Portfolio
Table 61. Nelson Labs Recent Development
Table 62. Texcell Company Information
Table 63. Texcell Business Overview
Table 64. Texcell Medical Device Viral Inactivation Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 65. Texcell Medical Device Viral Inactivation Testing Product Portfolio
Table 66. Texcell Recent Development
Table 67. Intertek Group Company Information
Table 68. Intertek Group Business Overview
Table 69. Intertek Group Medical Device Viral Inactivation Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 70. Intertek Group Medical Device Viral Inactivation Testing Product Portfolio
Table 71. Intertek Group Recent Development
Table 72. LabCorp Company Information
Table 73. LabCorp Business Overview
Table 74. LabCorp Medical Device Viral Inactivation Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 75. LabCorp Medical Device Viral Inactivation Testing Product Portfolio
Table 76. LabCorp Recent Development
Table 77. Syensqo Company Information
Table 78. Syensqo Business Overview
Table 79. Syensqo Medical Device Viral Inactivation Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Syensqo Medical Device Viral Inactivation Testing Product Portfolio
Table 81. Syensqo Recent Development
Table 82. SGS Company Information
Table 83. SGS Business Overview
Table 84. SGS Medical Device Viral Inactivation Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 85. SGS Medical Device Viral Inactivation Testing Product Portfolio
Table 86. SGS Recent Development
Table 87. Pacific BioLabs Company Information
Table 88. Pacific BioLabs Business Overview
Table 89. Pacific BioLabs Medical Device Viral Inactivation Testing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 90. Pacific BioLabs Medical Device Viral Inactivation Testing Product Portfolio
Table 91. Pacific BioLabs Recent Development
Table 92. Creative Biogene Company Information
Table 93. Creative Biogene Business Overview
Table 94. Creative Biogene Medical Device Viral Inactivation Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 95. Creative Biogene Medical Device Viral Inactivation Testing Product Portfolio
Table 96. Creative Biogene Recent Development
Table 97. ProPharma Group Company Information
Table 98. ProPharma Group Business Overview
Table 99. ProPharma Group Medical Device Viral Inactivation Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 100. ProPharma Group Medical Device Viral Inactivation Testing Product Portfolio
Table 101. ProPharma Group Recent Development
Table 102. Cormica Lab (Wickham Micro) Company Information
Table 103. Cormica Lab (Wickham Micro) Business Overview
Table 104. Cormica Lab (Wickham Micro) Medical Device Viral Inactivation Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 105. Cormica Lab (Wickham Micro) Medical Device Viral Inactivation Testing Product Portfolio
Table 106. Cormica Lab (Wickham Micro) Recent Development
Table 107. CTI Company Information
Table 108. CTI Business Overview
Table 109. CTI Medical Device Viral Inactivation Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 110. CTI Medical Device Viral Inactivation Testing Product Portfolio
Table 111. CTI Recent Development
Table 112. WuXi AppTec Company Information
Table 113. WuXi AppTec Business Overview
Table 114. WuXi AppTec Medical Device Viral Inactivation Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 115. WuXi AppTec Medical Device Viral Inactivation Testing Product Portfolio
Table 116. WuXi AppTec Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Authors List of This Report
Table 119. Secondary Sources
Table 120. Primary Sources
List of Figures
Figure 1. Medical Device Viral Inactivation Testing Product Image
Figure 2. Global Medical Device Viral Inactivation Testing Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Medical Device Viral Inactivation Testing Market Size (2021-2032) & (US$ Million)
Figure 4. Global Medical Device Viral Inactivation Testing Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. DNA-based Image
Figure 8. RNA-based Image
Figure 9. Global Medical Device Viral Inactivation Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global Medical Device Viral Inactivation Testing Sales Value Share 2021 VS 2025 VS 2032
Figure 11. Global Medical Device Viral Inactivation Testing Sales Value Share by Type (2021-2032)
Figure 12. Active Implant Medical Devices Image
Figure 13. Active Medical Equipment Image
Figure 14. In Vitro Diagnostic Equipment Image
Figure 15. Ophthalmic Medical Equipment Image
Figure 16. Vascular Medical Equipment Image
Figure 17. Other Image
Figure 18. Global Medical Device Viral Inactivation Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 19. Global Medical Device Viral Inactivation Testing Sales Value Share 2021 VS 2025 VS 2032
Figure 20. Global Medical Device Viral Inactivation Testing Sales Value Share by Application (2021-2032)
Figure 21. Global Medical Device Viral Inactivation Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 22. Global Medical Device Viral Inactivation Testing Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 23. North America Medical Device Viral Inactivation Testing Sales Value (2021-2032) & (US$ Million)
Figure 24. North America Medical Device Viral Inactivation Testing Sales Value Share by Country (%), 2025 VS 2032
Figure 25. Europe Medical Device Viral Inactivation Testing Sales Value (2021-2032) & (US$ Million)
Figure 26. Europe Medical Device Viral Inactivation Testing Sales Value Share by Country (%), 2025 VS 2032
Figure 27. Asia-Pacific Medical Device Viral Inactivation Testing Sales Value (2021-2032) & (US$ Million)
Figure 28. Asia-Pacific Medical Device Viral Inactivation Testing Sales Value Share by Country (%), 2025 VS 2032
Figure 29. South America Medical Device Viral Inactivation Testing Sales Value (2021-2032) & (US$ Million)
Figure 30. South America Medical Device Viral Inactivation Testing Sales Value Share by Country (%), 2025 VS 2032
Figure 31. Middle East & Africa Medical Device Viral Inactivation Testing Sales Value (2021-2032) & (US$ Million)
Figure 32. Middle East & Africa Medical Device Viral Inactivation Testing Sales Value Share by Country (%), 2025 VS 2032
Figure 33. USA Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 34. USA Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 35. USA Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 36. Canada Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 37. Canada Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 38. Canada Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 39. Mexico Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 40. Mexico Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 41. Mexico Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 42. Germany Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 43. Germany Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 44. Germany Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 45. France Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 46. France Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 47. France Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 48. U.K. Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 49. U.K. Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 50. U.K. Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 51. Italy Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 52. Italy Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 53. Italy Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 54. Spain Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 55. Spain Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 56. Spain Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 57. Russia Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 58. Russia Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 59. Russia Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 60. Netherlands Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 61. Netherlands Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 62. Netherlands Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 63. Nordic Countries Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 64. Nordic Countries Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 65. Nordic Countries Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 66. China Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 67. China Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 68. China Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 69. Japan Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 70. Japan Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 71. Japan Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 72. South Korea Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 73. South Korea Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 74. South Korea Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 75. India Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 76. India Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 77. India Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 78. Australia Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 79. Australia Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 80. Australia Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 81. Southeast Asia Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 82. Southeast Asia Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 83. Southeast Asia Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 84. Brazil Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 85. Brazil Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 86. Brazil Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 87. Argentina Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 88. Argentina Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 89. Argentina Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 90. Chile Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 91. Chile Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 92. Chile Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 93. Colombia Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 94. Colombia Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 95. Colombia Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 96. Peru Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 97. Peru Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 98. Peru Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 99. Saudi Arabia Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 100. Saudi Arabia Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 101. Saudi Arabia Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 102. Israel Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 103. Israel Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 104. Israel Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 105. UAE Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 106. UAE Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 107. UAE Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 108. Turkey Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 109. Turkey Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 110. Turkey Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 111. Iran Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 112. Iran Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 113. Iran Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 114. Egypt Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 115. Egypt Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 116. Egypt Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 117. Years Considered
Figure 118. Research Process
Figure 119. Key Executives Interviewed
Scope & coverage.
Types
- DNA-based
- RNA-based
Applications
- Active Implant Medical Devices
- Active Medical Equipment
- In Vitro Diagnostic Equipment
- Ophthalmic Medical Equipment
- Vascular Medical Equipment
- Other
Companies covered
- Charles River
- Perfectus Biomed (NAMSA)
- Eurofins Scientific
- Nelson Labs
- Texcell
- Intertek Group
- LabCorp
- Syensqo
- SGS
- Pacific BioLabs
- Creative Biogene
- ProPharma Group
- Cormica Lab (Wickham Micro)
- CTI
- WuXi AppTec
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Medical Device Viral Inactivation Testing Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Medical Device Viral Inactivation Testing Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Medical Device Viral Inactivation Testing Market Dynamics
- 2.1 Medical Device Viral Inactivation Testing Industry Trends
- 2.2 Medical Device Viral Inactivation Testing Industry Drivers
- 2.3 Medical Device Viral Inactivation Testing Industry Opportunities and Challenges
- 2.4 Medical Device Viral Inactivation Testing Industry Restraints
3 Medical Device Viral Inactivation Testing Market by Company
- 3.1 Global Medical Device Viral Inactivation Testing Company Revenue Ranking in 2025
- 3.2 Global Medical Device Viral Inactivation Testing Revenue by Company (2021-2026)
- 3.3 Global Medical Device Viral Inactivation Testing Company Ranking (2024-2026)
- 3.4 Global Medical Device Viral Inactivation Testing Company Manufacturing Base and Headquarters
- 3.5 Global Medical Device Viral Inactivation Testing Company Product Type and Application
- 3.6 Global Medical Device Viral Inactivation Testing Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Medical Device Viral Inactivation Testing Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Medical Device Viral Inactivation Testing Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Medical Device Viral Inactivation Testing Market by Type
- 4.1 Medical Device Viral Inactivation Testing Type Introduction
- 4.1.1 DNA-based
- 4.1.2 RNA-based
- 4.2 Global Medical Device Viral Inactivation Testing Sales Value by Type
- 4.2.1 Global Medical Device Viral Inactivation Testing Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Medical Device Viral Inactivation Testing Sales Value by Type (2021-2032)
- 4.2.3 Global Medical Device Viral Inactivation Testing Sales Value Share by Type (2021-2032)
5 Medical Device Viral Inactivation Testing Market by Application
- 5.1 Medical Device Viral Inactivation Testing Application Introduction
- 5.1.1 Active Implant Medical Devices
- 5.1.2 Active Medical Equipment
- 5.1.3 In Vitro Diagnostic Equipment
- 5.1.4 Ophthalmic Medical Equipment
- 5.1.5 Vascular Medical Equipment
- 5.1.6 Other
- 5.2 Global Medical Device Viral Inactivation Testing Sales Value by Application
- 5.2.1 Global Medical Device Viral Inactivation Testing Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Medical Device Viral Inactivation Testing Sales Value by Application (2021-2032)
- 5.2.3 Global Medical Device Viral Inactivation Testing Sales Value Share by Application (2021-2032)
6 Medical Device Viral Inactivation Testing Regional Value Analysis
- 6.1 Global Medical Device Viral Inactivation Testing Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Medical Device Viral Inactivation Testing Sales Value by Region (2021-2032)
- 6.2.1 Global Medical Device Viral Inactivation Testing Sales Value by Region: 2021-2026
- 6.2.2 Global Medical Device Viral Inactivation Testing Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Medical Device Viral Inactivation Testing Sales Value (2021-2032)
- 6.3.2 North America Medical Device Viral Inactivation Testing Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Medical Device Viral Inactivation Testing Sales Value (2021-2032)
- 6.4.2 Europe Medical Device Viral Inactivation Testing Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Medical Device Viral Inactivation Testing Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Medical Device Viral Inactivation Testing Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Medical Device Viral Inactivation Testing Sales Value (2021-2032)
- 6.6.2 South America Medical Device Viral Inactivation Testing Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Medical Device Viral Inactivation Testing Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Medical Device Viral Inactivation Testing Sales Value Share by Country, 2025 VS 2032
7 Medical Device Viral Inactivation Testing Country-level Value Analysis
- 7.1 Global Medical Device Viral Inactivation Testing Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Medical Device Viral Inactivation Testing Sales Value by Country (2021-2032)
- 7.2.1 Global Medical Device Viral Inactivation Testing Sales Value by Country (2021-2026)
- 7.2.2 Global Medical Device Viral Inactivation Testing Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.7.2 France Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.14.2 China Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.17.2 India Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Medical Device Viral Inactivation Testing Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Medical Device Viral Inactivation Testing Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Medical Device Viral Inactivation Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Charles River
- 8.1.1 Charles River Company Information
- 8.1.2 Charles River Business Overview
- 8.1.3 Charles River Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.1.4 Charles River Medical Device Viral Inactivation Testing Product Portfolio
- 8.1.5 Charles River Recent Developments
- 8.2 Perfectus Biomed (NAMSA)
- 8.2.1 Perfectus Biomed (NAMSA) Company Information
- 8.2.2 Perfectus Biomed (NAMSA) Business Overview
- 8.2.3 Perfectus Biomed (NAMSA) Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.2.4 Perfectus Biomed (NAMSA) Medical Device Viral Inactivation Testing Product Portfolio
- 8.2.5 Perfectus Biomed (NAMSA) Recent Developments
- 8.3 Eurofins Scientific
- 8.3.1 Eurofins Scientific Company Information
- 8.3.2 Eurofins Scientific Business Overview
- 8.3.3 Eurofins Scientific Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.3.4 Eurofins Scientific Medical Device Viral Inactivation Testing Product Portfolio
- 8.3.5 Eurofins Scientific Recent Developments
- 8.4 Nelson Labs
- 8.4.1 Nelson Labs Company Information
- 8.4.2 Nelson Labs Business Overview
- 8.4.3 Nelson Labs Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.4.4 Nelson Labs Medical Device Viral Inactivation Testing Product Portfolio
- 8.4.5 Nelson Labs Recent Developments
- 8.5 Texcell
- 8.5.1 Texcell Company Information
- 8.5.2 Texcell Business Overview
- 8.5.3 Texcell Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.5.4 Texcell Medical Device Viral Inactivation Testing Product Portfolio
- 8.5.5 Texcell Recent Developments
- 8.6 Intertek Group
- 8.6.1 Intertek Group Company Information
- 8.6.2 Intertek Group Business Overview
- 8.6.3 Intertek Group Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.6.4 Intertek Group Medical Device Viral Inactivation Testing Product Portfolio
- 8.6.5 Intertek Group Recent Developments
- 8.7 LabCorp
- 8.7.1 LabCorp Company Information
- 8.7.2 LabCorp Business Overview
- 8.7.3 LabCorp Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.7.4 LabCorp Medical Device Viral Inactivation Testing Product Portfolio
- 8.7.5 LabCorp Recent Developments
- 8.8 Syensqo
- 8.8.1 Syensqo Company Information
- 8.8.2 Syensqo Business Overview
- 8.8.3 Syensqo Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.8.4 Syensqo Medical Device Viral Inactivation Testing Product Portfolio
- 8.8.5 Syensqo Recent Developments
- 8.9 SGS
- 8.9.1 SGS Company Information
- 8.9.2 SGS Business Overview
- 8.9.3 SGS Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.9.4 SGS Medical Device Viral Inactivation Testing Product Portfolio
- 8.9.5 SGS Recent Developments
- 8.10 Pacific BioLabs
- 8.10.1 Pacific BioLabs Company Information
- 8.10.2 Pacific BioLabs Business Overview
- 8.10.3 Pacific BioLabs Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.10.4 Pacific BioLabs Medical Device Viral Inactivation Testing Product Portfolio
- 8.10.5 Pacific BioLabs Recent Developments
- 8.11 Creative Biogene
- 8.11.1 Creative Biogene Company Information
- 8.11.2 Creative Biogene Business Overview
- 8.11.3 Creative Biogene Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.11.4 Creative Biogene Medical Device Viral Inactivation Testing Product Portfolio
- 8.11.5 Creative Biogene Recent Developments
- 8.12 ProPharma Group
- 8.12.1 ProPharma Group Company Information
- 8.12.2 ProPharma Group Business Overview
- 8.12.3 ProPharma Group Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.12.4 ProPharma Group Medical Device Viral Inactivation Testing Product Portfolio
- 8.12.5 ProPharma Group Recent Developments
- 8.13 Cormica Lab (Wickham Micro)
- 8.13.1 Cormica Lab (Wickham Micro) Company Information
- 8.13.2 Cormica Lab (Wickham Micro) Business Overview
- 8.13.3 Cormica Lab (Wickham Micro) Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.13.4 Cormica Lab (Wickham Micro) Medical Device Viral Inactivation Testing Product Portfolio
- 8.13.5 Cormica Lab (Wickham Micro) Recent Developments
- 8.14 CTI
- 8.14.1 CTI Company Information
- 8.14.2 CTI Business Overview
- 8.14.3 CTI Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.14.4 CTI Medical Device Viral Inactivation Testing Product Portfolio
- 8.14.5 CTI Recent Developments
- 8.15 WuXi AppTec
- 8.15.1 WuXi AppTec Company Information
- 8.15.2 WuXi AppTec Business Overview
- 8.15.3 WuXi AppTec Medical Device Viral Inactivation Testing Revenue and Gross Margin (2021-2026)
- 8.15.4 WuXi AppTec Medical Device Viral Inactivation Testing Product Portfolio
- 8.15.5 WuXi AppTec Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst